This month’s aesthetic medicine industry news covers the most important changes affecting your patients, protocols, and practice growth. From new devices to safety alerts, this roundup gives you the insights you need—without the overwhelm.
This month’s aesthetic medicine industry news covers the most important changes affecting your patients, protocols, and practice growth. From new devices to safety alerts, this roundup gives you the insights you need—without the overwhelm.
GLP-1 trends in June 2025 are redefining obesity treatment—but real-world data reveals more than half of patients quit within a year. This article explores why, what’s coming next, and how providers can adapt to a rapidly changing landscape.
This month’s aesthetic medicine industry news covers the most important changes affecting your patients, protocols, and practice growth. From new devices to safety alerts, this roundup gives you the insights you need—without the overwhelm.
Botox patient satisfaction now defines success in modern aesthetic practice. This guide shows new injectors how to capture feedback, build trust, and grow their business.
Semaglutide is effective for weight loss—but nearly 35% of that loss can be lean muscle. The COURAGE trial from Regeneron explores a novel antibody co-therapy that may protect muscle and improve fat loss outcomes, setting a new bar for obesity treatment.
The FDA has issued a public safety warning about unsafe OTC numbing products with dangerously high lidocaine concentrations. Aesthetic providers should review the list of flagged products and adjust their protocols to avoid liability and patient harm.
Starting an aesthetic practice can feel overwhelming — but it doesn’t have to be. These four essential pillars will guide you toward building a successful, independent, and sustainable aesthetic practice with confidence.
May 2025 brought conclusive evidence that tirzepatide (Zepbound) produces substantially greater weight loss than semaglutide (Wegovy), with SURMOUNT-5 trial participants losing approximately 20% body weight on tirzepatide versus 14% on semaglutide. Beyond superior weight loss efficacy, GLP-1 medications demonstrated expanded therapeutic benefits for liver disease, cardiovascular health, sleep apnea, and even reduced alcohol consumption, transforming how providers should conceptualize these therapies from ‘weight loss drugs’ to comprehensive metabolic and organ-protective agents.
What Providers Need to Know Now: May 2025 GLP-1 Updates GLP-1 medications continue to make headlines—and for good reason. These powerful agents are proving useful